WuXi Biologics (Cayman) (BMV:2269 N) - Stock Price, News & Analysis

2269 N Stock Overview

2269 N fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	3/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 52% below our estimate of its fair value

Earnings are forecast to grow 17.12% per year

Earnings grew by 1.7% over the past year

Risk Analysis

Shares are highly illiquid

WuXi Biologics (Cayman) Inc. Competitors

Hangzhou Tigermed Consulting

SZSE:300347

CN¥46.6b

Stevanato Group

NYSE:STVN

US$7.5b

Medpace Holdings

NasdaqGS:MEDP

US$12.2b

Bachem Holding

SWX:BANB

CHF6.1b

Price History & Performance

Summary of all time highs, changes and price drops for WuXi Biologics (Cayman)
Historical stock prices
Current Share Price	HK$62.53
52 Week High	HK$62.53
52 Week Low	HK$62.53
Beta	0.66
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	-74.45%
5 Year Change	n/a
Change since IPO	-73.63%

Recent updates

Shareholder Returns

	2269 N	MX Life Sciences	MX Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how 2269 N performed against the MX Life Sciences industry.

Return vs Market: Insufficient data to determine how 2269 N performed against the MX Market.

Price Volatility

Is 2269 N's price volatile compared to industry and market?
2269 N volatility
2269 N Average Weekly Movement	n/a
Life Sciences Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: 2269 N has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 2269 N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2014	12,397	Chris Chen	www.wuxibiologics.com

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development, and manufacturing in the People’s Republic of China, North America, Europe, and internationally. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates.

WuXi Biologics (Cayman) Inc. Fundamentals Summary

How do WuXi Biologics (Cayman)'s earnings and revenue compare to its market cap?
2269 N fundamental statistics
Market cap	Mex$132.67b
Earnings (TTM)	Mex$9.71b
Revenue (TTM)	Mex$38.71b

13.7x

P/E Ratio

3.4x

P/S Ratio

Is 2269 N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2269 N income statement (TTM)
Revenue	CN¥16.55b
Cost of Revenue	CN¥9.68b
Gross Profit	CN¥6.87b
Other Expenses	CN¥2.72b
Earnings	CN¥4.15b

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Mar 26, 2024

Earnings per share (EPS)	0.99
Gross Margin	41.51%
Net Profit Margin	25.08%
Debt/Equity Ratio	7.7%

How did 2269 N perform over the long term?

See historical performance and comparison

2269 N Stock Overview

Rewards

Risk Analysis

WuXi Biologics (Cayman) Inc. Competitors

SZSE:300347

CN¥46.6b

NYSE:STVN

US$7.5b

NasdaqGS:MEDP

US$12.2b

SWX:BANB

CHF6.1b

Price History & Performance

Recent News & Updates

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P Global 1200

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Recent updates

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P Global 1200

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Investor sentiment deteriorates as stock falls 26%

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Less than half of directors are independent

CEO & Executive Director recently sold Mex$45m worth of stock

Investor sentiment improved over the past week

Less than half of directors are independent

Less than half of directors are independent

Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021

WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Substance Facility MFG5

CEO & Executive Director recently bought Mex$102m worth of stock

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

CEO & Executive Director recently sold Mex$88m worth of stock

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.27 in FY 2019)

Insider recently bought Mex$9.2m worth of stock

Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.27 in FY 2019)

WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed to acquire a 90% stake in CMAB Biopharma Inc. from CBC Group.

WuXi Biologics (Cayman) Inc. (SEHK:2269) entered into an equity agreement to acquire Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

Exelixis, Inc. Enters into License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline

Wuxi Biologics (Cayman) Inc. Receives Remote Pre-Approval Inspection by European Medicines Agency on MFG4 Facility

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Antengene Corporation Limited Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage

Executive VP recently sold Mex$275m worth of stock

Oxford BioTherapeutics Ltd Designates Second Bispecific Antibody Program Leveraging Wuxi Biologics’ Wuxibody® Platform

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform

WuXi Biologics Receives GMP Certification from Brazil's ANVISA

Shareholder Returns

Price Volatility

About the Company